Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Rheumatoid Arthritis - Pipeline Review, H2 2016

By: Global Markets Direct
, Published: Dec-2016
, Product code: GMDHC8865IDB
Key Insights
    • The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
    • The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
    • The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    • The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Companies mentioned in this product:

3SBio Inc 4D Pharma Plc A&G Pharmaceutical Inc AB Science SA AB2 Bio Ltd AbbVie Inc Ablynx NV ACEA Biosciences Inc Addex Therapeutics Ltd Adello Biologics LLC Advinus Therapeutics Ltd AlphaMab Co Ltd Alteogen Inc Amgen Inc Amura Holdings Ltd Anacor Pharmaceuticals Inc AnGes MG Inc Applied Genetic Technologies Corp Aptevo Therapeutics Inc ARA Healthcare Pvt Ltd Arena Pharmaceuticals Inc arGEN-X BV Arrien Pharmaceuticals LLC Arthrogen BV Asahi Kasei Pharma Corp Asana BioSciences LLC Astellas Pharma Inc AstraZeneca Plc Atlantic Bio Sci LLC Aurigene Discovery Technologies Ltd Avexxin AS Axxam SpA BCN Peptides SA Beijing Hanmi Pharmaceutical Co Ltd Bio-Cancer Treatment International Ltd Biocad Biocon Ltd Biokine Therapeutics Ltd BioLingus AG BioLite Inc Bionovis SA BioTherapeutics Inc Biozeus Bird Rock Bio Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Can-Fite BioPharma Ltd Cardax Inc CASI Pharmaceuticals Inc CEL-SCI Corp Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Celltrion Inc ChemoCentryx Inc Chipscreen Biosciences Ltd ChironWells GmbH Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Clevexel Pharma SA CLL Pharma SA Coherus BioSciences Inc Commence Bio Inc Compugen Ltd Confluence Life Sciences Inc CSL Ltd Cyclacel Pharmaceuticals Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd Diamyd Medical AB Domainex Ltd Dong-A Socio Holdings Co Ltd Dr. Reddy's Laboratories Ltd Eisai Co Ltd Eli Lilly and Company Enceladus Pharmaceuticals BV Endocyte Inc Enzene Biosciences Ltd F. Hoffmann-La Roche Ltd Fountain Biopharma Inc Galapagos NV Gene Techno Science Co Ltd Genentech Inc Genor BioPharma Co Ltd Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Griffin Discoveries BV Han Wha Pharma Co Ltd Handok Inc Hanmi Pharmaceuticals Co Ltd Hansa Medical AB Hanwha Chemical Corp HEC Pharm Co Ltd Hetero Drugs Ltd HitGen LTD Huabo Biopharm Co Ltd Humabs BioMed SA Hutchison MediPharma Ltd Idera Pharmaceuticals Inc Idogen AB Iltoo Pharma Immune Response BioPharma Inc Immune Therapeutics Inc Immungenetics AG ImmunoFrontier Inc Immupharma Plc Innate Pharma SA Innovent Biologics Inc Intas Pharmaceuticals Ltd Japan Tobacco Inc JHL Biotech Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Jyant Technologies Inc Kadmon Corp LLC KAHR medical Ltd Kang Stem Biotech Co Ltd Karus Therapeutics Ltd Karyopharm Therapeutics Inc KPI Therapeutics Inc Lead Pharma Holding BV Lexicon Pharmaceuticals Inc LG Life Science LTD Lipocure Ltd Livzon Pharmaceutical Group Inc LSK BioPartners Inc Lupin Ltd Mabion SA Mabtech Ltd mAbxience SA MacroGenics Inc Mebiopharm Co Ltd MedAnnex Ltd Medestea Research & Production SpA MediGene AG MedImmune LLC Merck KGaA Mesoblast Ltd Millennium Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp Modern Biosciences Plc ModiQuest Group Momenta Pharmaceuticals Inc Morphotek Inc Mycenax Biotech Inc MYOS RENS Technology Inc Myungmoon pharmaceutical Co Ltd NanoSmart Pharmaceuticals Inc Navigen Pharmaceuticals Inc NeuClone Pty Ltd Nissan Chemical Industries Ltd Novartis AG NovelMed Therapeutics Inc NovImmune SA Nuevolution AB Omeros Corp Oncobiologics Inc Oncodesign SA OncoImmune Inc Ono Pharmaceutical Co Ltd Opsona Therapeutics Ltd Oscotec Inc OSE Immunotherapeutics Panacea Biotec Ltd Paras Biopharmaceuticals Finland Oy Parvus Therapeutics Inc Peptinov SAS Pfenex Inc Pfizer Inc Pharmacyclics Inc Pharmedartis GmbH Philogen SpA PLx Pharma Inc Portola Pharmaceuticals Inc Principia Biopharma Inc Progenra Inc ProNoxis AB Protab Ltd Protalex Inc Protalix BioTherapeutics Inc Qu Biologics Inc R Pharm Re-Pharm Ltd ReceptoPharm Inc RedHill Biopharma Ltd Redx Pharma Plc Regeneron Pharmaceuticals Inc Reliance Life Sciences Pvt Ltd Resverlogix Corp ReveraGen BioPharma Inc Rhizen Pharmaceuticals SA Ribomic Inc Richter Gedeon Nyrt Saje Pharma LLC Sandoz International GmbH Sareum Holdings Plc SBI Biotech Co Ltd Selecta Biosciences Inc Selvita SA Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Henlius Biotech Co Ltd Shanghai Pharmaceutical Co Ltd Spherium Biomed SL Synovo GmbH Syntrix Biosystems Inc Takeda Pharmaceutical Company Ltd TechnoPhage SA Teijin Pharma Ltd The International Biotechnology Center (IBC) Generium TheraMAB LLC Toleranzia AB Tumorend LLC TxCell SA U.S. Stem Cell Inc UCB SA United BioPharma Inc Vaccinex Inc Valeant Pharmaceuticals International Inc VentiRx Pharmaceuticals Inc Vicore Pharma AB viDA Therapeutics Inc Vitae Pharmaceuticals Inc Vitaeris Inc Xbrane Biopharma AB Xencor Inc XL-protein GmbH XTL Biopharmaceuticals Ltd Yungjin Pharm Co Ltd Yuyu Pharma Inc Zenith Capital Corp Zenyaku Kogyo Co Ltd Zydus Cadila Healthcare Ltd
Table of Contents
Table of Contents
Table of Contents 2
Introduction 12
Rheumatoid Arthritis Overview 13
Therapeutics Development 14
Rheumatoid Arthritis - Therapeutics under Development by Companies 16
Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36
Rheumatoid Arthritis - Pipeline Products Glance 39
Rheumatoid Arthritis - Products under Development by Companies 43
Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 72
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 75
Rheumatoid Arthritis - Therapeutics Assessment 308
Drug Profiles 355
Rheumatoid Arthritis - Dormant Projects 1046
Rheumatoid Arthritis - Discontinued Products 1098
Rheumatoid Arthritis - Product Development Milestones 1110
Appendix 1134
Tables and Figures
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H2 2016 65
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 68
Number of Products under Development by Companies, H2 2016 (Contd..1) 69
Number of Products under Development by Companies, H2 2016 (Contd..2) 70
Number of Products under Development by Companies, H2 2016 (Contd..3) 71
Number of Products under Development by Companies, H2 2016 (Contd..4) 72
Number of Products under Development by Companies, H2 2016 (Contd..5) 73
Number of Products under Development by Companies, H2 2016 (Contd..6) 74
Number of Products under Development by Companies, H2 2016 (Contd..7) 75
Number of Products under Development by Companies, H2 2016 (Contd..8) 76
Number of Products under Development by Companies, H2 2016 (Contd..9) 77
Number of Products under Development by Companies, H2 2016 (Contd..10) 78
Number of Products under Development by Companies, H2 2016 (Contd..11) 79
Number of Products under Development by Companies, H2 2016 (Contd..12) 80
Number of Products under Development by Companies, H2 2016 (Contd..13) 81
Number of Products under Development by Companies, H2 2016 (Contd..14) 82
Number of Products under Development by Companies, H2 2016 (Contd..15) 83
Number of Products under Development by Companies, H2 2016 (Contd..16) 84
Number of Products under Development by Companies, H2 2016 (Contd..17) 85
Number of Products under Development by Companies, H2 2016 (Contd..18) 86
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 88
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 89
Comparative Analysis by Late Stage Development, H2 2016 90
Comparative Analysis by Clinical Stage Development, H2 2016 91
Comparative Analysis by Early Stage Development, H2 2016 92
Comparative Analysis by Unknown Stage Development, H2 2016 93
Products under Development by Companies, H2 2016 94
Products under Development by Companies, H2 2016 (Contd..1) 95
Products under Development by Companies, H2 2016 (Contd..2) 96
Products under Development by Companies, H2 2016 (Contd..3) 97
Products under Development by Companies, H2 2016 (Contd..4) 98
Products under Development by Companies, H2 2016 (Contd..5) 99
Products under Development by Companies, H2 2016 (Contd..6) 100
Products under Development by Companies, H2 2016 (Contd..7) 101
Products under Development by Companies, H2 2016 (Contd..8) 102
Products under Development by Companies, H2 2016 (Contd..9) 103
Products under Development by Companies, H2 2016 (Contd..10) 104
Products under Development by Companies, H2 2016 (Contd..11) 105
Products under Development by Companies, H2 2016 (Contd..12) 106
Products under Development by Companies, H2 2016 (Contd..13) 107
Products under Development by Companies, H2 2016 (Contd..14) 108
Products under Development by Companies, H2 2016 (Contd..15) 109
Products under Development by Companies, H2 2016 (Contd..16) 110
Products under Development by Companies, H2 2016 (Contd..17) 111
Products under Development by Companies, H2 2016 (Contd..18) 112
Products under Development by Companies, H2 2016 (Contd..19) 113
Products under Development by Companies, H2 2016 (Contd..20) 114
Products under Development by Companies, H2 2016 (Contd..21) 115
Products under Development by Companies, H2 2016 (Contd..22) 116
Products under Development by Companies, H2 2016 (Contd..23) 117
Products under Development by Companies, H2 2016 (Contd..24) 118
Products under Development by Companies, H2 2016 (Contd..25) 119
Products under Development by Companies, H2 2016 (Contd..26) 120
Products under Development by Companies, H2 2016 (Contd..27) 121
Products under Development by Companies, H2 2016 (Contd..28) 122
Products under Investigation by Universities/Institutes, H2 2016 123
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 124
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 125
Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2016 126
Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2016 127
Rheumatoid Arthritis - Pipeline by A&G Pharmaceutical Inc, H2 2016 128
Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2016 129
Rheumatoid Arthritis - Pipeline by AB2 Bio Ltd, H2 2016 130
Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2016 131
Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2016 132
Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H2 2016 133
Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2016 134
Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H2 2016 135
Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H2 2016 136
Rheumatoid Arthritis - Pipeline by AlphaMab Co Ltd, H2 2016 137
Rheumatoid Arthritis - Pipeline by Alteogen Inc, H2 2016 138
Rheumatoid Arthritis - Pipeline by Amgen Inc, H2 2016 139
Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd, H2 2016 140
Rheumatoid Arthritis - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 141
Rheumatoid Arthritis - Pipeline by AnGes MG Inc, H2 2016 142
Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H2 2016 143
Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H2 2016 144
Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 145
Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 146
Rheumatoid Arthritis - Pipeline by arGEN-X BV, H2 2016 147
Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 148
Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2016 149
Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H2 2016 150
Rheumatoid Arthritis - Pipeline by Asana BioSciences LLC, H2 2016 151
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H2 2016 152
Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H2 2016 153
Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H2 2016 154
Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 155
Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2016 156
Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2016 157
Rheumatoid Arthritis - Pipeline by BCN Peptides SA, H2 2016 158
Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 159
Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 160
Rheumatoid Arthritis - Pipeline by Biocad, H2 2016 161
Rheumatoid Arthritis - Pipeline by Biocon Ltd, H2 2016 162
Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd, H2 2016 163
Rheumatoid Arthritis - Pipeline by BioLingus AG, H2 2016 164
Rheumatoid Arthritis - Pipeline by BioLite Inc, H2 2016 165
Rheumatoid Arthritis - Pipeline by Bionovis SA, H2 2016 166
Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc, H2 2016 167
Rheumatoid Arthritis - Pipeline by Biozeus, H2 2016 168
Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H2 2016 169
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 170
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 171
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H2 2016 172
Rheumatoid Arthritis - Pipeline by Cardax Inc, H2 2016 173
Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 174
Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H2 2016 175
Rheumatoid Arthritis - Pipeline by Celgene Corp, H2 2016 176
Rheumatoid Arthritis - Pipeline by Cellceutix Corp, H2 2016 177
Rheumatoid Arthritis - Pipeline by Celldex Therapeutics Inc, H2 2016 178
Rheumatoid Arthritis - Pipeline by Celltrion Inc, H2 2016 179
Rheumatoid Arthritis - Pipeline by ChemoCentryx Inc, H2 2016 180
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2016 181
Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2016 182
Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 183
Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H2 2016 184
Rheumatoid Arthritis - Pipeline by Clevexel Pharma SA, H2 2016 185
Rheumatoid Arthritis - Pipeline by CLL Pharma SA, H2 2016 186
Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H2 2016 187
Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H2 2016 188
Rheumatoid Arthritis - Pipeline by Compugen Ltd, H2 2016 189
Rheumatoid Arthritis - Pipeline by Confluence Life Sciences Inc, H2 2016 190
Rheumatoid Arthritis - Pipeline by CSL Ltd, H2 2016 191
Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 192
Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 193
Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 194
Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H2 2016 195
Rheumatoid Arthritis - Pipeline by Domainex Ltd, H2 2016 196
Rheumatoid Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 197
Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 198
Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H2 2016 199
Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2016 200
Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 201
Rheumatoid Arthritis - Pipeline by Endocyte Inc, H2 2016 202
Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H2 2016 203
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 204
Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H2 2016 205
Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2016 206
Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H2 2016 207
Rheumatoid Arthritis - Pipeline by Genentech Inc, H2 2016 208
Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016 209
Rheumatoid Arthritis - Pipeline by Genosco Inc, H2 2016 210
Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H2 2016 211
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H2 2016 212
Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2016 213
Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H2 2016 214
Rheumatoid Arthritis - Pipeline by Handok Inc, H2 2016 215
Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 216
Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H2 2016 217
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H2 2016 218
Rheumatoid Arthritis - Pipeline by HEC Pharm Co Ltd, H2 2016 219
Rheumatoid Arthritis - Pipeline by Hetero Drugs Ltd, H2 2016 220

List of Figures
Number of Products under Development for Rheumatoid Arthritis, H2 2016 65
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 67
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Comparative Analysis by Late Stage Development, H2 2016 90
Comparative Analysis by Clinical Stage Development, H2 2016 91
Comparative Analysis by Early Stage Products, H2 2016 92
Assessment by Monotherapy Products, H2 2016 359
Number of Products by Top 10 Targets, H2 2016 361
Number of Products by Stage and Top 10 Targets, H2 2016 361
Number of Products by Top 10 Mechanism of Actions, H2 2016 381
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 381
Number of Products by Top 10 Routes of Administration, H2 2016 402
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 402
Number of Products by Top 10 Molecule Types, H2 2016 404
Number of Products by Stage and Top 10 Molecule Types, H2 2016 404
Sample Pages

Request Sample Pages

Rheumatoid Arthritis - Pipeline Review, H2 2016
By: Global Markets Direct
Published: Dec 2016
Contact Details


Download Brochure

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Synopsis

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons To Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Quick Overview

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

More information about Rheumatoid Arthritis - Pipeline Review, H2 2016

For more information on this report or to speak to one of our experts

Call us on +44(0)20 7936 6830 or Email us

Related Reports

mail

For more information
on this report or to speak to one of our experts

Email us or call us on
+44(0)20 7936 6830

Purchase

Site License - This allows anybody within a business at the same site to view the report.

Single-user - This allows only one person to view the report.

Enterprise License -  This allows anybody globally within the organisation to view the report.

Preview Report

For a free preview of this report please complete our simple form.

Request
mail

Read our latest
Industry Insights Blog
and stay informed